Literature DB >> 32112202

Tumor Microenvironment Mediators CD8+- and FOXP3+-Labeled T Lymphocytes Are Prospective Prognosticators in Curatively Treated Rectal Cancer Patients.

Hala Zaghloul1, Ahmed Abbas2, Dina Abdulah3.   

Abstract

PURPOSE: To explore the implication of CD8+- and FOXP3+-labeled T lymphocytes invading tumor microenvironment in prognosticating curatively treated rectal cancer with preoperative chemo-radiation.
METHODS: The diagnostic rectal biopsies from clinical T3-T4 and any nodal diseases or any T stage with nodal involvement were processed to quantify (CD8+and FOXP3+). The impact of tested indicators on the achieved pathologic response among other clinical-pathological variables was particularized. Additionally, the prognosticating eventuality of labeled T lymphocytes for survival was elaborated using Log-rank and Cox regression.
RESULTS: We selected fifty rectal patients who had negative surgical margins following preoperative chemo-radiation for clinical T3-T4 or any T stage with nodal involvement. The higher expressions of CD8+ and CD8+/FOXP3+, and the reduced FOXP3+incursion were interrelated with the lack of nodal and lympho-vascular invasion alongside accentuated pathologic response. Additionally, the augmented densities of FOXP3+ ≥ 120, the reduced CD8+/FOXP3+ ratio < 0.96, and the nodal incursion were considerably linked with the worsened OS [hazard ratio (HR) 2.37 (95% confidence interval (CI), 2.38-11.27), 2.41 (95% CI, 2.14-7.12), and 2.63 (95% CI, 2.81-5.32)], and dismal DFS [HR 2.61 (95% CI, 1.58-6.12), 3.12 (95% CI, 2.15-7.24), and 3.32 (95% CI, 2.47-9.24)], respectively.
CONCLUSION: The augmented expressions of CD8+ and C8+/FOXP3+ together with the reduced densities of FOXP3+ exhibited a substantial contribution to the attained pathological response and were linked to improved clinical-pathological characteristics of cancer rectum patients treated with chemo-radiation preceding mesorectal excision. Additionally, they can be authorized as reliable individual prognosticators of clinical outcomes.

Entities:  

Keywords:  CD8+; Cancer; FOXP3+; Prognosticators; Rectal; T Lymphocytes

Mesh:

Substances:

Year:  2021        PMID: 32112202     DOI: 10.1007/s12029-020-00376-1

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  22 in total

1.  CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells.

Authors:  Richard J DiPaolo; Deborah D Glass; Karen E Bijwaard; Ethan M Shevach
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

2.  The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Authors:  Dominik Wolf; Anna M Wolf; Holger Rumpold; Heidi Fiegl; Alain G Zeimet; Elisabeth Muller-Holzner; Martina Deibl; Guenther Gastl; Eberhard Gunsilius; Christian Marth
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

3.  Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

Authors:  Nobuyoshi Hiraoka; Kaoru Onozato; Tomoo Kosuge; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 4.  Naturally arising CD25+CD4+ regulatory T cells in tumor immunity.

Authors:  T Nomura; S Sakaguchi
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

7.  Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.

Authors:  Dermot S O'Callaghan; Elton Rexhepaj; Kathy Gately; Linda Coate; David Delaney; Dearbhaile M O'Donnell; Elaine Kay; Finbarr O'Connell; William M Gallagher; Kenneth J O'Byrne
Journal:  Eur Respir J       Date:  2015-11-05       Impact factor: 16.671

Review 8.  Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis.

Authors:  Z Mei; Y Liu; C Liu; A Cui; Z Liang; G Wang; H Peng; L Cui; C Li
Journal:  Br J Cancer       Date:  2014-02-06       Impact factor: 7.640

9.  FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis.

Authors:  Miki Takenaka; Naoko Seki; Uhi Toh; Satoshi Hattori; Akihiko Kawahara; Tomohiko Yamaguchi; Keiko Koura; Ryuji Takahashi; Hiroko Otsuka; Hiroki Takahashi; Nobutaka Iwakuma; Shino Nakagawa; Teruhiko Fujii; Tetsuro Sasada; Rin Yamaguchi; Hirohisa Yano; Kazuo Shirouzu; Masayoshi Kage
Journal:  Mol Clin Oncol       Date:  2013-04-26

10.  The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study.

Authors:  Jonna Berntsson; Maria C Svensson; Karin Leandersson; Björn Nodin; Patrick Micke; Anna H Larsson; Jakob Eberhard; Karin Jirström
Journal:  Int J Cancer       Date:  2017-07-20       Impact factor: 7.396

View more
  1 in total

Review 1.  Tumor-Infiltrating Lymphocytes as Biomarkers of Treatment Response and Long-Term Survival in Patients with Rectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Adile Orhan; Faisal Khesrawi; Michael Tvilling Madsen; Rasmus Peuliche Vogelsang; Niclas Dohrn; Anne-Marie Kanstrup Fiehn; Ismail Gögenur
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.